Biocomposites Partners with InfectoTest to Enhance Infection Testing
Biocomposites, a leader in medical device innovation, is making strides to revolutionize the diagnosis of periprosthetic joint infections (PJI). Their latest investment in InfectoTest GmbH, developers of a groundbreaking point-of-care test called InfectoSynovia, reflects the company's dedication to improving infection management in surgical settings.
Introducing InfectoSynovia: A Game-Changer in Infection Diagnosis
InfectoSynovia is being engineered for speed and precision, with the potential to deliver accurate PJI diagnoses in under five minutes. This innovative test utilizes a unique electrochemical method to assess minimal quantities of synovial fluid, achieving remarkable sensitivity and specificity.
The Importance of Quick Diagnosis
As joint replacement surgeries increase globally, the incidence of PJI poses significant challenges for healthcare professionals. Current estimates indicate that PJI affects over two percent of hip and knee arthroplasty patients. The fast and accurate identification of the causative bacteria is critical for tailoring effective surgical or antimicrobial treatments for patients suffering from these infections.
Unique Detection Capabilities
InfectoTest's cutting-edge technology enables the detection of low-grade and culture-negative infections, which are often difficult to identify using conventional methods. With just 50 microliters of synovial fluid needed for analysis, the potential to enhance patient outcomes by facilitating quicker treatment decisions is enormous.
Expert Insights from Industry Leaders
Michael Harris, the Chief Executive Officer of Biocomposites, emphasized the pressing need for effective diagnostic solutions, stating, "Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximize their chances of full recovery." This investment solidifies Biocomposites' ongoing commitment to advancing medical technologies that target infections in bone and soft tissue.
Support from InfectoTest's Leadership
Svetlana Karbysheva, Managing Director of InfectoTest, highlighted the potential impact of their collaboration. She remarked, "Our InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection. With the backing of Biocomposites, we can accelerate development and expedite the delivery of this critical diagnostic tool to clinics and patients alike." This partnership not only enhances the capabilities of both companies but also underscores a shared vision for improving patient care in the realm of infection management.
About Biocomposites: A Leader in Infection Management
Biocomposites is renowned for its expertise in crafting cutting-edge medical devices that address infection risks related to surgical procedures. As a company dedicated to innovation, it operates on a global scale, reaching markets in various regions, including Europe, South America, the USA, Canada, China, and India. Their extensive portfolio is based on pioneering calcium compounds and specialty polymers, which serve to regenerate bone and mitigate infection risk across multiple medical specialties.
Global Reach and Impact
With their products utilized in over one million procedures annually and distributed across more than 100 countries, Biocomposites' influence is undeniable. They are committed to providing healthcare professionals with the highest-quality products to help combat infections effectively.
About InfectoTest: Innovation in Diagnostics
InfectoTest GmbH operates with a clear mission: to transform infectious disease diagnostics. By developing advanced point-of-care testing solutions, they aim to optimize the diagnostic process, ensuring timely and appropriate treatments for patients. Their collaboration with Biocomposites marks a significant step forward in achieving their goals.
Frequently Asked Questions
What is the main purpose of the InfectoSynovia test?
The InfectoSynovia test aims to provide rapid and accurate diagnosis of periprosthetic joint infections in under five minutes.
How does InfectoTest's electrochemical analysis work?
This method allows for the detection of infections from small amounts of synovial fluid, enhancing sensitivity and specificity in diagnostic outcomes.
Why is quick diagnosis important for PJI?
Fast diagnosis is crucial to ensure that patients receive the most effective surgical or antimicrobial treatment quickly, which can improve recovery outcomes.
What is Biocomposites' role in this partnership?
Biocomposites has invested in InfectoTest to help advance the development and distribution of innovative diagnostic tools for infection management.
Where can I learn more about Biocomposites' products?
You can find more information about Biocomposites and their product offerings on their official website.
